Open AccessBiomarkers of Potential Harm: Summary of an FDA-Sponsored Public Workshop
Author(s) -
Cindy M. Chang,
Yu-Ching Cheng,
Taehyeon M. Cho,
Elena V. Mishina,
Arseima Y. Del Valle-Pinero,
Dana M. van Bemmel,
Dorothy K. Hatsukami
Publication year - 2017
Publication title -
nicotine and tobacco research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.338
H-Index - 113
eISSN - 1469-994X
pISSN - 1462-2203
DOI - 10.1093/ntr/ntx273
Subject(s) - harm , medicine , medline , environmental health , political science , law
Since 2009, the United States (US) Food and Drug Administration (FDA) Center for Tobacco Products (CTP) has had the authority to regulate the manufacture, distribution, and marketing of tobacco products in order to reduce the death and disease caused by tobacco use. Biomarkers could play an important role across a number of FDA regulatory activities, including assessing new and modified risk tobacco products and identifying and evaluating potential product standards.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom